MD-76R Drug Patent Profile
✉ Email this page to a colleague
When do Md-76r patents expire, and when can generic versions of Md-76r launch?
Md-76r is a drug marketed by Liebel-flarsheim and is included in one NDA.
The generic ingredient in MD-76R is diatrizoate meglumine; diatrizoate sodium. There are eleven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the diatrizoate meglumine; diatrizoate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Md-76r
A generic version of MD-76R was approved as diatrizoate meglumine; diatrizoate sodium by ANDA REPOSITORY on June 27th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MD-76R?
- What are the global sales for MD-76R?
- What is Average Wholesale Price for MD-76R?
Summary for MD-76R
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Patent Applications: | 190 |
| DailyMed Link: | MD-76R at DailyMed |
US Patents and Regulatory Information for MD-76R
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liebel-flarsheim | MD-76R | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 019292-001 | Sep 29, 1989 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
